Recruiting

Multimodal Training Effects in Middle-Aged and Older Adults With Diabetic Sarcopenia

This study aims to investigate the effects of a 12-week multimodal exercise intervention on middle-aged and older adults (aged 45\~85 years) with Type 2 Diabetes Mellitus (T2DM). The program combines supervised training, home-based sessions, and digital support to improve muscle function, physical performance, metabolic control, and quality of life.

ClinicalTrials.gov IDNCT07398495

PhaseNA

Enrollment128

Sponsoryueh chu wu

Age45 Years

SexALL

I'm interested View official listing

Conditions studied

Type 2 Diabetes Mellitus (T2DM), Sarcopenia

About this study

Interventions

Behavioral: Multimodal Exercise Program — Participants will engage in a 12-week multimodal exercise program comprising supervised training sessions, home-based exercises, and digital support. To facilitate adherence and proper technique, participants will also receive a "Diabetes and Muscle Health Handbook" as a training guide.

Primary outcomes

Physical Function (5TSTS) (Change from Baseline at Week 12 and Week 24)
Handgrip Strength (HGS) (Change from Baseline at Week 12 and Week 24)
Skeletal Muscle Mass Index (SMI) (Change from Baseline at Week 12 and Week 24)
Sarcopenia Risk: Assessed using the Strength, Assistance with walking, Rise from a chair, Climb stairs, and Falls (SARC-F) questionnaire combined with calf circumference measurement (SARC-CalF). (Change from Baseline at Week 12 and Week 24)

Eligibility information

Inclusion Criteria: * Diagnosed with both Type 2 Diabetes Mellitus (T2DM) and sarcopenia. * Maintained on a stable regimen of oral hypoglycemic agents. * Aged 45 years or older. * Capable of communicating effectively in Mandarin or Taiwanese. * Willing to provide informed consent or have it obtained from a legally authorized representative. Exclusion Criteria: * • Limited limb or joint function that prevents exercise (e.g., recent fractures or dislocations). * Communication barriers or severe emotional/psychological issues (e.g., uncontrolled depression or severe mental illness). * Severe cognitive impairment (e.g., dementia). * End-stage renal disease (ESRD). * Major comorbidities or complications, including active diabetic foot ulcers, amputation, recent myocardial infarction, severe autonomic neuropathy, or a history of stroke within the last 3 years.

Study locations

Chung Shan Medical University Hospital, Taichung, Taiwan 402306 Taiwan

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.